{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:54:39Z","timestamp":1790729679184,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"publisher","award":["445757098"],"award-info":[{"award-number":["445757098"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003185","name":"Fraunhofer-Gesellschaft","doi-asserted-by":"publisher","award":["445757098"],"award-info":[{"award-number":["445757098"]}],"id":[{"id":"10.13039\/501100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2336"],"award-info":[{"award-number":["GRK 2336"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inhibitor of nuclear factor kappa-B kinase epsilon (IKK\u03b5) contributes to tumorigenesis and metastasis in various cancers. In melanoma, it is overexpressed and constitutively active. Inhibition of IKK\u03b5 by either knockdown or pharmaceutical compounds reduce tumor progression by suppressing key molecular pathways within melanoma tumor cells. However, within the tumor microenvironment (TME), the role of this protein remains to be fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multiplex immunohistochemistry was performed on human primary melanomas to assess IKK\u03b5 expression in tumor and immune cell compartments. In the mouse model, B16BL6 melanoma cells were injected subcutaneously into the flanks of wildtype and IKK\u03b5-deficient mice, and tumor growth was monitored over time. Flow-cytometric analyses characterized intratumoral immune cell populations in both genotypes, followed by in vivo CD8\u207a T-cell depletion to determine their contribution to tumor control. To elucidate molecular mechanisms underlying the differential tumor growth, we conducted targeted and untargeted proteomic analyses, which indicated regulation of angiogenic pathways which were further examined by assessing specific protein changes in tumor tissue and performing in vitro angiogenesis assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The reduced tumor growth observed in IKK\u03b5 knock-out (KO) mice was concomitant with elevated levels of cytotoxic CD8\u207a and \u03b3\u03b4-T-cells, and a diminished presence of neutrophils. Furthermore, our data revealed that isolated CD8\u207a T-cells from IKK\u03b5 KO mice exhibited a higher activity in comparison to their wildtype counterparts. In addition, the depletion of CD8\u207a cells reversed the antitumor efficacy of IKK\u03b5 depletion.<\/jats:p>\n                    <jats:p>Proteomic analysis of tumor lysates revealed a reduction of several chemokines in IKK\u03b5 KO mice compared to wildtype controls, that might contribute to the reduced tumor growth and suggested that an inhibition of angiogenesis may support the antitumor activity in IKK\u03b5 KO mice. This hypothesis could be confirmed by further protein analyses and angiogenesis assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data imply that IKK\u03b5 expression in melanoma is not only important in the tumor cells but also in the tumor microenvironment by regulation of the immune response and angiogenesis. Consequently, inhibition of IKK\u03b5 may offer a novel therapeutic approach for melanoma, complementing existing therapies that target pathways within tumor cells and antitumor immune responses in the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01651-w","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:43:20Z","timestamp":1790725400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity"],"prefix":"10.1186","volume":"32","author":[{"given":"Michelle","family":"Ha\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Benning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerina","family":"Aliraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"H\u00e4upl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimo","family":"Kannt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Geisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-5751","authenticated-orcid":false,"given":"Ellen","family":"Niederberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"9","key":"1651_CR1","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.4049\/jimmunol.165.9.5269","volume":"165","author":"CL Addison","year":"2000","unstructured":"Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000;165(9):5269\u201377.","journal-title":"J Immunol"},{"issue":"37","key":"1651_CR2","doi-asserted-by":"publisher","first-page":"26976","DOI":"10.1074\/jbc.M603133200","volume":"281","author":"M Adli","year":"2006","unstructured":"Adli M, Baldwin AS. IKK-i\/IKKe controls constitutive, cancer cell-associated NF-B activity via regulation of Ser-536 p65\/RelA phosphorylation. J Biol Chem. 2006;281(37):26976\u201384.","journal-title":"J Biol Chem."},{"key":"1651_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1651_CR4","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1073\/pnas.95.11.6355","volume":"95","author":"AM Babic","year":"1998","unstructured":"Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998;95(11):6355\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1651_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1651_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00336-2","volume":"5","author":"MV Blagosklonny","year":"2004","unstructured":"Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004;5(1):13\u20137.","journal-title":"Cancer Cell"},{"issue":"5732","key":"1651_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309(5732):264\u20138.","journal-title":"Science"},{"issue":"21","key":"1651_CR8","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1651_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000100878","volume":"214","author":"JA Campillo","year":"2007","unstructured":"Campillo JA, Martinez-Escribano JA, Minguela A, Lopez-Alvarez R, Marin LA, Garcia-Alonso AM, et al. Increased number of cytotoxic CD3+ CD28- gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma. Dermatology (Basel). 2007;214(4):283\u20138.","journal-title":"Dermatology (Basel)"},{"issue":"9","key":"1651_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/cr.2008.273","volume":"18","author":"JF Clement","year":"2008","unstructured":"Clement JF, Meloche S, Servant MJ. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 2008;18(9):889\u201399.","journal-title":"Cell Res"},{"issue":"3","key":"1651_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2003.10.009","volume":"14","author":"I Conti","year":"2004","unstructured":"Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol. 2004;14(3):149\u201354.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"1651_CR12","doi-asserted-by":"publisher","first-page":"e49878","DOI":"10.1371\/journal.pone.0049878","volume":"7","author":"A Cordova","year":"2012","unstructured":"Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, et al. Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS ONE. 2012;7(11):e49878.","journal-title":"PLoS ONE"},{"issue":"8","key":"1651_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1651_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1189\/jlb.72.1.9","volume":"72","author":"P Dhawan","year":"2002","unstructured":"Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002;72(1):9\u201318.","journal-title":"J Leukoc Biol"},{"issue":"24","key":"1651_CR15","first-page":"7335","volume":"62","author":"P Dhawan","year":"2002","unstructured":"Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt\/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 2002;62(24):7335\u201342.","journal-title":"Cancer Res"},{"issue":"8","key":"1651_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/2159-8290.CD-16-0955","volume":"7","author":"B Eskiocak","year":"2017","unstructured":"Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, et al. Biomarker accessible and chemically addressable mechanistic subtypes of BRAF melanoma. Cancer Discov. 2017;7(8):832\u201351.","journal-title":"Cancer Discov"},{"issue":"1","key":"1651_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/0008-5472.CAN-09-2326","volume":"70","author":"ZG Fridlender","year":"2010","unstructured":"Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010;70(1):109\u201318.","journal-title":"Cancer Res"},{"issue":"3","key":"1651_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1084\/jem.20030584","volume":"198","author":"Y Gao","year":"2003","unstructured":"Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198(3):433\u201342.","journal-title":"J Exp Med"},{"issue":"8","key":"1651_CR19","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"1","key":"1651_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jlb.67.1.53","volume":"67","author":"H Haghnegahdar","year":"2000","unstructured":"Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, et al. The tumorigenic and angiogenic effects of MGSA\/GRO proteins in melanoma. J Leukoc Biol. 2000;67(1):53\u201362.","journal-title":"J Leukoc Biol"},{"issue":"12","key":"1651_CR21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20040520","volume":"199","author":"H Hemmi","year":"2004","unstructured":"Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004;199(12):1641\u201350.","journal-title":"J Exp Med"},{"issue":"1","key":"1651_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009a;4(1):44\u201357.","journal-title":"Nat Protoc"},{"issue":"1","key":"1651_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009b;37(1):1\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"1651_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbrc.2007.10.182","volume":"365","author":"M Koga","year":"2008","unstructured":"Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun. 2008;365(2):279\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"1651_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020792","author":"J Korbecki","year":"2022","unstructured":"Korbecki J, Barczak K, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CXCL1: gene, promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23020792.","journal-title":"Int J Mol Sci"},{"key":"1651_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101674","author":"J Korbecki","year":"2025","unstructured":"Korbecki J, Bosiacki M, Pilarczyk M, Kot M, Defort P, Walaszek I, et al. The CXCL1-CXCR2 axis as a component of therapy resistance, a source of side effects in cancer treatment, and a therapeutic target. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17101674.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1651_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.biochi.2010.11.010","volume":"93","author":"L Kular","year":"2011","unstructured":"Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C. The CCN family: a new class of inflammation modulators? Biochimie. 2011;93(3):377\u201388.","journal-title":"Biochimie"},{"issue":"9","key":"1651_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"4","author":"EC Lerner","year":"2023","unstructured":"Lerner EC, Woroniecka KI, D\u2019Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, et al. CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023;4(9):1258\u201372.","journal-title":"Nat Cancer"},{"key":"1651_CR29","doi-asserted-by":"publisher","first-page":"1572909","DOI":"10.3389\/fcell.2025.1572909","volume":"13","author":"L Liu","year":"2025","unstructured":"Liu L, Yu J, Liu Y, Xie L, Hu F, Liu H. Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors. Front Cell Dev Biol. 2025;13:1572909.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"1651_CR30","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"1651_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"1651_CR32","unstructured":"Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. Epidemiology of Melanoma. In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU). 2017."},{"issue":"10","key":"1651_CR33","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1074\/jbc.M508045200","volume":"281","author":"I Mattioli","year":"2006","unstructured":"Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, et al. Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J Biol Chem. 2006;281(10):6175\u201383.","journal-title":"J Biol Chem"},{"issue":"2","key":"1651_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-0749.2004.00128.x","volume":"17","author":"SE McNulty","year":"2004","unstructured":"McNulty SE, del Rosario R, Cen D, Meyskens FL Jr, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004;17(2):173\u201380.","journal-title":"Pigment Cell Res."},{"issue":"13","key":"1651_CR35","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.3390\/ijms21134721","volume":"21","author":"M Moller","year":"2020","unstructured":"Moller M, Wasel J, Schmetzer J, Weiss U, Meissner M, Schiffmann S, et al. The specific IKKepsilon\/TBK1 inhibitor amlexanox suppresses human melanoma by the inhibition of autophagy, NF-kappaB and MAP kinase pathways. Int J Mol Sci. 2020;21(13):4721.","journal-title":"Int J Mol Sci."},{"issue":"5","key":"1651_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.171.5.1797","volume":"171","author":"B Moser","year":"1990","unstructured":"Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med. 1990;171(5):1797\u2013802.","journal-title":"J Exp Med"},{"issue":"5","key":"1651_CR37","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.4049\/jimmunol.1004088","volume":"187","author":"CV Moser","year":"2011","unstructured":"Moser CV, Kynast K, Baatz K, Russe OQ, Ferreiros N, Costiuk H, et al. The protein kinase IKKepsilon is a potential target for the treatment of inflammatory hyperalgesia. J Immunol. 2011;187(5):2617\u201325.","journal-title":"J Immunol"},{"key":"1651_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bcp.2015.12.016","volume":"103","author":"CV Moser","year":"2016","unstructured":"Moser CV, Meissner M, Laarmann K, Olbrich K, King-Himmelreich TS, Wolters MC, et al. The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model. Biochem Pharmacol. 2016;103:64\u201373.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1651_CR39","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1084\/jem.181.1.435","volume":"181","author":"LA Pekarek","year":"1995","unstructured":"Pekarek LA, Starr BA, Toledano AY, Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995;181(1):435\u201340.","journal-title":"J Exp Med"},{"issue":"21","key":"1651_CR40","first-page":"4849","volume":"57","author":"L Peng","year":"1997","unstructured":"Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res. 1997;57(21):4849\u201354.","journal-title":"Cancer Res"},{"issue":"2","key":"1651_CR41","first-page":"M57","volume":"1471","author":"RT Peters","year":"2001","unstructured":"Peters RT, Maniatis T. A new family of IKK-related kinases may function as I kappa B kinase kinases. Biochim Biophys Acta. 2001;1471(2):M57-62.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1651_CR42","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1097-2765(00)80445-1","volume":"5","author":"RT Peters","year":"2000","unstructured":"Peters RT, Liao SM, Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell. 2000;5(3):513\u201322.","journal-title":"Mol Cell"},{"issue":"5","key":"1651_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1074\/mcp.M116.065524","volume":"16","author":"DL Plubell","year":"2017","unstructured":"Plubell DL, Wilmarth PA, Zhao Y, Fenton AM, Minnier J, Reddy AP, et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol Cell Proteomics. 2017;16(5):873\u201390.","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"1651_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","volume":"3","author":"S Rey","year":"2017","unstructured":"Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer. 2017;3(7):529\u201341.","journal-title":"Trends Cancer"},{"issue":"6","key":"1651_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/onc.2010.493","volume":"30","author":"RR Shen","year":"2011","unstructured":"Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011;30(6):631\u201341.","journal-title":"Oncogene"},{"issue":"7","key":"1651_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","volume":"19","author":"B Silva-Santos","year":"2019","unstructured":"Silva-Santos B, Mensurado S, Coffelt SB. gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019;19(7):392\u2013404.","journal-title":"Nat Rev Cancer"},{"issue":"45","key":"1651_CR47","doi-asserted-by":"publisher","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","volume":"270","author":"RM Strieter","year":"1995","unstructured":"Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270(45):27348\u201357.","journal-title":"J Biol Chem"},{"issue":"2","key":"1651_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-019-03388-5","volume":"146","author":"R Tamura","year":"2020","unstructured":"Tamura R, Morimoto Y, Sato M, Kuranari Y, Oishi Y, Kosugi K, et al. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. J Neurooncol. 2020;146(2):265\u201373.","journal-title":"J Neurooncol"},{"issue":"6779","key":"1651_CR49","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/35008109","volume":"404","author":"Y Tojima","year":"2000","unstructured":"Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, et al. NAK is an IkappaB kinase-activating kinase. Nature. 2000;404(6779):778\u201382.","journal-title":"Nature"},{"issue":"9","key":"1651_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13(9):731\u201340.","journal-title":"Nat Methods"},{"issue":"8","key":"1651_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1415","volume":"4","author":"J Vakkila","year":"2004","unstructured":"Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4(8):641\u20138.","journal-title":"Nat Rev Immunol"},{"issue":"51","key":"1651_CR52","doi-asserted-by":"publisher","first-page":"30619","DOI":"10.1074\/jbc.270.51.30619","volume":"270","author":"LD Wood","year":"1995","unstructured":"Wood LD, Richmond A. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity\/GRO alpha gene requires both NF-kappa B and novel constitutive factors. J Biol Chem. 1995;270(51):30619\u201326.","journal-title":"J Biol Chem"},{"key":"1651_CR53","doi-asserted-by":"publisher","first-page":"116783","DOI":"10.1016\/j.biopha.2024.116783","volume":"176","author":"M Yang","year":"2024","unstructured":"Yang M, Mu Y, Yu X, Gao D, Zhang W, Li Y, et al. Survival strategies: how tumor hypoxia microenvironment orchestrates angiogenesis. Biomed Pharmacother. 2024;176:116783.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1651_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1101\/gad.14.2.163","volume":"14","author":"Q Yu","year":"2000","unstructured":"Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14(2):163\u201376.","journal-title":"Genes Dev"},{"issue":"2","key":"1651_CR55","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.celrep.2016.05.083","volume":"16","author":"J Zhang","year":"2016","unstructured":"Zhang J, Feng H, Zhao J, Feldman ER, Chen SY, Yuan W, et al. IkappaB Kinase epsilon Is an NFATc1 Kinase that Inhibits T Cell Immune Response. Cell Rep. 2016;16(2):405\u201318.","journal-title":"Cell Rep"},{"key":"1651_CR56","doi-asserted-by":"publisher","first-page":"102180","DOI":"10.1016\/j.tice.2023.102180","volume":"84","author":"L Zhu","year":"2023","unstructured":"Zhu L, Guo G, Jin Y, Hu A, Liu Y. IKBKE regulates angiogenesis by modulating VEGF expression and secretion in glioblastoma. Tissue Cell. 2023;84:102180.","journal-title":"Tissue Cell"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01651-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:55:23Z","timestamp":1790726123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01651-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01651-w","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.O. received research funding from Gilead and Merck KGaA, is a consultant\/received honoraria for\/from Beigene, BMS, Roche, Regeneron, Janssen, Lilly, Merck KGaA, Gilead, Genmab, Kronos Bio, Sobi and Abbvie (all not related to this work).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"167"}}